EDB GlobalConnect Certified Technology Partnership
We are excited to announce that Chemaxon is now an EDB GlobalConnect Certified Technology Partner.
CertaraApril 12, 2023
FDA awards new grants to support developing & assessing complex generic drugs
Certara’s Simcyp physiologically-based pharmacokinetic (PBPK) Simulator is being used to verify and expand biosimulation models…
CertaraFebruary 7, 2023
Certara Awarded NIH Contract for Toxicology Consulting Support
Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…
CertaraJanuary 10, 2023
Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme
PRINCETON, N.J., January 9, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,…
CertaraJanuary 9, 2023
Certara Announces New Release of PK Submit
PRINCETON, N.J.— October 12, 2022 – Certara, Inc., a global leader in drug development software,…
CertaraOctober 12, 2022
Certara Earns 2022 Great Place to Work Certification™
Princeton, NJ, May 17, 2022. Certara, Inc., a global leader in biosimulation, today announced that…
CertaraMay 17, 2022
P21 Adds Support for CDISC Open Rules Engine (CORE)
P21 is proud to announce that support for CDISC Open Rules Engine (CORE) is now available…
CertaraApril 25, 2022
Pinnacle 21 Releases P21 Community 4.0
As of April 25, 2022, we have released P21 Community 4.0 to general availability! Install…
CertaraApril 25, 2022
Certara Selected by the European Medicines Agency to Provide Real World Solutions for Critical Regulatory Decisions
Princeton, N.J., March 17, 2022 -- Certara, Inc. today announced a four-year, framework service contract…
CertaraMarch 17, 2022
Certara Acquires Integrated Nonclinical Development Solutions
Expands software portfolio and nonclinical drug development expertise PRINCETON, N.J.— Jan 5, 2022– Certara, Inc.,…
CertaraJanuary 5, 2022
